October 2007 Oncology News International

Point/Counterpoint

• Patient selection key to appropriate use of early ADT

Spotlight on Cancer Centers

• Dana-Farber over half way to $1 billion funding goal

Focus on Breast Cancer

• Radiation therapy for DCIS: Controversial or standard of care?

• Neoadjuvant trastuzumab increases pCR rate

• First-line sunitinib/paclitaxel promising in advanced breast ca

Focus on Prostate Cancer

• Sling helps restore bladder control after prostatectomy

• Tumor shrinkage explains excess high-grade cancers in PCPT

• Bill aims to 'revitalize' FDA by adding powers and databases

Focus on Colon Cancer

• Colon ca chemo: Sequencing or upfront combinations?

Focus on Lung Cancer

• BRCA1 overexpression is strongly linked to poor outcome in NSCLC patients treated with cisplatin

• Good survival results in phase II study of ASA404 in NSCLC

Cancer Care & Economics

• Changing risky behavior: What is the government's role in helping people reduce their risk of cancer?

• The ESA controversy as seen from a payer's viewpoint

• The SGR: The madness behind physician payment fee cuts

• Bailes new ASCO Foundation chair

Technology Watch

• PEM joins fray in breast cancer diagnosis and screening

Reporter at Large

• Dr. Rai and the B cells; Dr. Chiorazzi and the B-cell receptors

Focus on Hematology

• FDG-PET predicts Hodgkin's lymphoma chemo response

• New myeloma trial results; two new studies initiated

• Treanda gets FDA orphan drug status for CLL